Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HeartSciences (HSCS) Research & Development (2021 - 2026)

HeartSciences' Research & Development history spans 6 years, with the latest figure at $638575.0 for Q1 2026.

  • For Q1 2026, Research & Development fell 38.19% year-over-year to $638575.0; the TTM value through Jan 2026 reached $3.3 million, down 26.9%, while the annual FY2025 figure was $4.4 million, 52.37% up from the prior year.
  • Research & Development reached $638575.0 in Q1 2026 per HSCS's latest filing, down from $727026.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.4 million in Q2 2022 to a low of $434198.0 in Q3 2022.
  • Average Research & Development over 5 years is $831939.9, with a median of $757303.0 recorded in 2023.
  • Peak YoY movement for Research & Development: plummeted 60.58% in 2023, then soared 116.56% in 2024.
  • A 5-year view of Research & Development shows it stood at $848976.0 in 2022, then dropped by 10.8% to $757303.0 in 2023, then surged by 58.32% to $1.2 million in 2024, then plummeted by 39.36% to $727026.0 in 2025, then fell by 12.17% to $638575.0 in 2026.
  • Per Business Quant, the three most recent readings for HSCS's Research & Development are $638575.0 (Q1 2026), $727026.0 (Q4 2025), and $997206.0 (Q3 2025).